Autonomic Diabetic Polyneuropathy Variants: Possible Correction

Objective of the Review: To analyse the incidence of polyneuropathy in diabetic patients focusing on autonomic neuropathy. Key Points. Polyneuropathy is one of the most common delayed complications of diabetes mellitus (DM); the condition has numerous clinical aspects. Major polyneuropathy studies focus on assessment, prevention and management of pain caused by sensory and sensory-and-motor defects, prevention of ulceration and Charcot foot. At the same time, various autonomic neuropathy variants in diabetic patients have either been studied not thoroughly enough, or are outside of clinical interest. Still, prevention and pathogenic effect from autonomic neuropathy are similar to those used in other types of diabetic neuropathy. We describe major pathogenic links in nerve fibre damaging and clinical forms of autonomic neuropathy. Major studies of the use of α-lipoic acid in DM are presented. Conclusion. α-lipoic acid medications are efficient in slowing down various forms of autonomic neuropathy. Dose-dependent action of these medications, adequate therapy duration (at least 3 months as a course of medication), improved glycaemic control in patients with DM are essential for autonomic neuropathy prevention and slowing down.